Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era
暂无分享,去创建一个
J. Fantini | H. Chahinian | N. Yahi | Fodil Azzaz | F. Azzaz
[1] C. Mukhopadhyay,et al. Identification of possible binding modes of SARS-CoV-2 spike N-terminal domain for ganglioside GM1 , 2022, Chemical Physics Letters.
[2] B. Scola,et al. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects , 2022, bioRxiv.
[3] J. Fantini,et al. A Vaccine Strategy Based on the Identification of an Annular Ganglioside Binding Motif in Monkeypox Virus Protein E8L , 2022, Viruses.
[4] J. Fantini,et al. The Epigenetic Dimension of Protein Structure Is an Intrinsic Weakness of the AlphaFold Program , 2022, Biomolecules.
[5] Mujahed I. Mustafa,et al. Novel multi epitope-based vaccine against monkeypox virus: vaccinomic approach , 2022, Scientific Reports.
[6] J. Tomaskova,et al. Cellular Lipids—Hijacked Victims of Viruses , 2022, Viruses.
[7] A. Baj,et al. Monkeypox: An international epidemic , 2022, Reviews in medical virology.
[8] M. Koopmans,et al. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct , 2022, Science Immunology.
[9] Michael M. Desai,et al. Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1 , 2022, bioRxiv.
[10] J. Fantini,et al. Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes , 2022, Molecules.
[11] M. Haddadi,et al. Antiviral effects of azithromycin: A narrative review , 2022, Biomedicine & Pharmacotherapy.
[12] B. La Scola,et al. The puzzling mutational landscape of the SARS‐2‐variant Omicron , 2022, Journal of medical virology.
[13] Catherine Z. Chen,et al. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry , 2022, SLAS Discovery.
[14] Jie-Li Hu,et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron , 2021, Cellular & Molecular Immunology.
[15] J. Fantini,et al. Ganglioside binding domains in proteins: Physiological and pathological mechanisms. , 2022, Advances in protein chemistry and structural biology.
[16] S. Pascarella,et al. The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta‐plus variants: A hint to higher transmissibility? , 2021, Journal of medical virology.
[17] J. Diallo,et al. Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern , 2021, ACS infectious diseases.
[18] Catherine Z. Chen,et al. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry , 2021, bioRxiv.
[19] V. Pravica,et al. Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? , 2021, Viruses.
[20] J. Fantini,et al. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks , 2021, Journal of Infection.
[21] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[22] G. Barton,et al. Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics , 2021, bioRxiv.
[23] Md. Mujibur Rahman,et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial , 2021, The Journal of international medical research.
[24] Xue-Long Sun. The role of cell surface sialic acids for SARS-CoV-2 infection , 2021, Glycobiology.
[25] A. Cook,et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial , 2021, International Journal of Infectious Diseases.
[26] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.
[27] L. Bao,et al. Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2 , 2021, Acta Pharmaceutica Sinica B.
[28] J. López-Guerrero,et al. Membrane Rafts: Portals for Viral Entry , 2021, Frontiers in Microbiology.
[29] A. Javadi,et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial , 2020, Asian Pacific Journal of Tropical Medicine.
[30] M. Taha,et al. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2 , 2020, Cells.
[31] F. X. Qin,et al. Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin , 2020, Cell proliferation.
[32] J. Fantini,et al. Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19 , 2020, Biochemical and Biophysical Research Communications.
[33] D. Jans,et al. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? , 2020, Cells.
[34] M. Saviano,et al. A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment , 2020, Frontiers in Molecular Biosciences.
[35] Francesco Filippini,et al. Normal modes analysis and surface electrostatics of haemagglutinin proteins as fingerprints for high pathogenic type A influenza viruses , 2020, BMC Bioinformatics.
[36] M. Farzan,et al. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 , 2020, bioRxiv.
[37] J. Sodroski,et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.
[38] G. Melino,et al. Is hydroxychloroquine beneficial for COVID-19 patients? , 2020, Cell Death & Disease.
[39] J. Fantini,et al. Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers? , 2020, Protein science : a publication of the Protein Society.
[40] Emanuele Rizzo. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.
[41] S. D. Fernando,et al. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review , 2020, Clinical Microbiology and Infection.
[42] J. Fantini,et al. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal , 2020, International Journal of Antimicrobial Agents.
[43] D. Raoult,et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect , 2020, Microbial Pathogenesis.
[44] Jacques Fantini,et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.
[45] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[46] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[47] J. Küpper,et al. Variations in Proteins Dielectric Constants , 2020, ChemistryOpen.
[48] T. Geijtenbeek,et al. Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1 , 2019, Front. Immunol..
[49] M. J. Robertson,et al. Structural Insights into Metabotropic Glutamate Receptor Activation , 2018, Nature.
[50] J. McFadden,et al. The origins of quantum biology , 2018, Proceedings of the Royal Society A.
[51] M. Maginnis. Virus–Receptor Interactions: The Key to Cellular Invasion , 2018, Journal of Molecular Biology.
[52] G. Ayora-Talavera. Sialic acid receptors: focus on their role in influenza infection , 2018 .
[53] F. Filippini,et al. Electrostatic Variation of Haemagglutinin as a Hallmark of the Evolution of Avian Influenza Viruses , 2018, Scientific Reports.
[54] Oh,et al. Sialic acid receptors: focus on their role in influenza infection , 2018 .
[55] M. Tortorici,et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein , 2017, Proceedings of the National Academy of Sciences.
[56] V. Lee,et al. Polysulfonate suramin inhibits Zika virus infection , 2017, Antiviral research.
[57] B. Schnierle,et al. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry , 2016, Virology Journal.
[58] R. Schnaar. Gangliosides of the Vertebrate Nervous System. , 2016, Journal of molecular biology.
[59] D. Raoult,et al. Fighting viruses with antibiotics: an overlooked path , 2016, International Journal of Antimicrobial Agents.
[60] G. Simmons,et al. Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins. , 2016, Current gene therapy.
[61] Aiping Wu,et al. Antigenic Patterns and Evolution of the Human Influenza A (H1N1) Virus , 2015, Scientific Reports.
[62] Johannes E. Schindelin,et al. The ImageJ ecosystem: An open platform for biomedical image analysis , 2015, Molecular reproduction and development.
[63] J. Fantini,et al. Brain Lipids in Synaptic Function and Neurological Disease: Clues to Innovative Therapeutic Strategies for Brain Disorders , 2015 .
[64] F. Filippini,et al. Comparative structural analysis of haemagglutinin proteins from type A influenza viruses: conserved and variable features , 2014, BMC Bioinformatics.
[65] T. Stehle,et al. The sweet spot: defining virus–sialic acid interactions , 2014, Nature Reviews Microbiology.
[66] Rita Gerardy-Schahn,et al. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. , 2014, Physiological reviews.
[67] Thomas Lengauer,et al. Modelling binding between CCR5 and CXCR4 receptors and their ligands suggests the surface electrostatic potential of the co-receptor to be a key player in the HIV-1 tropism , 2013, Retrovirology.
[68] J. Castelán-Vega,et al. Analysis of Adaptation Mutants in the Hemagglutinin of the Influenza A(H1N1)pdm09 Virus , 2013, PloS one.
[69] Yoshihiro Kawaoka,et al. Receptor binding by a ferret-transmissible H5 avian influenza virus , 2013, Nature.
[70] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[71] D. Stallknecht,et al. Expression and distribution of sialic acid influenza virus receptors in wild birds , 2013, Avian pathology : journal of the W.V.P.A.
[72] P. Lio’,et al. The Puzzling Role of CXCR4 in Human Immunodeficiency Virus Infection , 2013, Theranostics.
[73] Ryan McBride,et al. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities , 2013, Proceedings of the National Academy of Sciences.
[74] Chun-ching Lin,et al. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry , 2013, BMC Microbiology.
[75] A. Osterhaus,et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.
[76] J. Fantini,et al. Selective transmigration of monocyte-associated HIV-1 across a human cervical monolayer and its modulation by seminal plasma , 2012, AIDS.
[77] Chris A Kieslich,et al. Clustering of HIV-1 Subtypes Based on gp120 V3 Loop electrostatic properties , 2012, BMC biophysics.
[78] Alexander D. MacKerell,et al. Glycan reader: Automated sugar identification and simulation preparation for carbohydrates and glycoproteins , 2011, J. Comput. Chem..
[79] Peter Politzer,et al. The electrostatic potential: an overview , 2011 .
[80] J. Grivel,et al. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? , 2011, Journal of Translational Medicine.
[81] E. Arts,et al. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. , 2011, The Lancet. Infectious diseases.
[82] R. E. Cunningham,et al. Role of Sialic Acid Binding Specificity of the 1918 Influenza Virus Hemagglutinin Protein in Virulence and Pathogenesis for Mice , 2009, Journal of Virology.
[83] H. Garg,et al. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry. , 2008, Antiviral research.
[84] M. Churchill,et al. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. , 2008, Virology.
[85] K. Dimock,et al. Sialic acid tissue distribution and influenza virus tropism , 2008, Influenza and other respiratory viruses.
[86] Sunhwan Jo,et al. PBEQ-Solver for online visualization of electrostatic potential of biomolecules , 2008, Nucleic Acids Res..
[87] J. Tam,et al. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells , 2008, Biochemical and Biophysical Research Communications.
[88] Anne Imberty,et al. N-Glycolyl GM1 Ganglioside as a Receptor for Simian Virus 40 , 2007, Journal of Virology.
[89] P. Auffinger,et al. Nucleic acid solvation: from outside to insight. , 2007, Current opinion in structural biology.
[90] K. Ikuta,et al. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle , 2006, Microbes and Infection.
[91] Anne Imberty,et al. N-Glycolyl GM 1 Ganglioside as a Receptor for Simian Virus 40 † , 2007 .
[92] Martin Chaplin,et al. Do we underestimate the importance of water in cell biology? , 2006, Nature Reviews Molecular Cell Biology.
[93] J. Fantini,et al. Prediction of glycolipid-binding domains from the amino acid sequence of lipid raft-associated proteins: application to HpaA, a protein involved in the adhesion of Helicobacter pylori to gastrointestinal cells. , 2006, Biochemistry.
[94] Robin Shattock,et al. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? , 2006, Nature Reviews Microbiology.
[95] Carlos L. Cesar,et al. Red blood cell membrane viscoelasticity, agglutination, and zeta potential measurements with double optical tweezers , 2006, SPIE BiOS.
[96] S. Huang,et al. Dimensions of systems biology. , 2006, Reviews of physiology, biochemistry and pharmacology.
[97] B. Verrier,et al. Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV , 2005, Journal of medical virology.
[98] Sebastian Bonhoeffer,et al. The HIV coreceptor switch: a population dynamical perspective. , 2005, Trends in microbiology.
[99] J. Rojo,et al. Glycodendritic structures: promising new antiviral drugs. , 2004, The Journal of antimicrobial chemotherapy.
[100] A. Lapedes,et al. Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.
[101] John P. Moore,et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.
[102] R. Weinstein. Planning for epidemics--the lessons of SARS. , 2004, The New England journal of medicine.
[103] A. Benesi,et al. Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. , 2004, Bioconjugate chemistry.
[104] C. Martínez-A,et al. Pathogens: raft hijackers , 2003, Nature Reviews Immunology.
[105] J. Fantini. How sphingolipids bind and shape proteins: molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains , 2003, Cellular and Molecular Life Sciences CMLS.
[106] L. Pike. Lipid rafts Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.R200021-JLR200 , 2003, Journal of Lipid Research.
[107] S. Philpott. HIV-1 coreceptor usage, transmission, and disease progression. , 2003, Current HIV research.
[108] J. Fantini,et al. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases , 2002, Expert Reviews in Molecular Medicine.
[109] A. Brigo,et al. The Poisson–Boltzmann equation for biomolecular electrostatics: a tool for structural biology , 2002, Journal of molecular recognition : JMR.
[110] J. Fantini,et al. Identification of a Common Sphingolipid-binding Domain in Alzheimer, Prion, and HIV-1 Proteins* , 2002, The Journal of Biological Chemistry.
[111] J. Fantini,et al. Amphiphilic anionic analogues of galactosylceramide: synthesis, anti-HIV-1 activity, and gp120 binding. , 2001, Journal of medicinal chemistry.
[112] J. Fantini,et al. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. , 2001, The Journal of infectious diseases.
[113] Jaap Goudsmit,et al. N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.
[114] A. Osterhaus,et al. Macrophage Tropism of Human Immunodeficiency Virus Type 1 Facilitates In Vivo Escape from Cytotoxic T-Lymphocyte Pressure , 2001, Journal of Virology.
[115] J. Sleasman,et al. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). , 2000, AIDS.
[116] C. Martínez-A,et al. Membrane raft microdomains mediate lateral assemblies required for HIV‐1 infection , 2000, EMBO reports.
[117] A M Aubertin,et al. Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity. , 2000, Carbohydrate research.
[118] D. Dimitrov,et al. Glycosphingolipids Promote Entry of a Broad Range of Human Immunodeficiency Virus Type 1 Isolates into Cell Lines Expressing CD4, CXCR4, and/or CCR5 , 2000, Journal of Virology.
[119] J. Sodroski,et al. Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120 , 2000, Journal of Virology.
[120] J. Fantini,et al. Human Erythrocyte Glycosphingolipids as Alternative Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1) Entry: Evidence for CD4-Induced Interactions between HIV-1 gp120 and Reconstituted Membrane Microdomains of Glycosphingolipids (Gb3 and GM3) , 1999, Journal of Virology.
[121] H. Gelberg,et al. Structure and Function of a Ganglioside Receptor for Porcine Rotavirus , 1998, Journal of Virology.
[122] J. Fantini,et al. Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells. , 1998, Virology.
[123] W. Im,et al. Continuum solvation model: Computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation , 1998 .
[124] J. Fantini,et al. Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of glycolipids as potential HIV-1 fusion cofactors. , 1998, Biochemical and biophysical research communications.
[125] J. Fantini,et al. Specific Interaction of HIV-1 and HIV-2 Surface Envelope Glycoproteins with Monolayers of Galactosylceramide and Ganglioside GM3* , 1998, The Journal of Biological Chemistry.
[126] J. Albert,et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.
[127] J. Fantini,et al. HIV-1 transmission across the vaginal epithelium. , 1997, AIDS.
[128] A. Trkola,et al. Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.
[129] J. Fantini,et al. Synthetic Soluble Analogs of Galactosylceramide (GalCer) Bind to the V3 Domain of HIV-1 gp120 and Inhibit HIV-1-induced Fusion and Entry* , 1997, The Journal of Biological Chemistry.
[130] J. Fantini,et al. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. , 1996, Biochemistry.
[131] B. Honig,et al. Classical electrostatics in biology and chemistry. , 1995, Science.
[132] J. Fantini,et al. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[133] M. Wainberg,et al. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection , 1995 .
[134] J. Fantini,et al. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line , 1995, Journal of virology.
[135] J. Fantini,et al. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. , 1994, The Journal of biological chemistry.
[136] Y. Suzuki,et al. Gangliosides as influenza virus receptors. Variation of influenza viruses and their recognition of the receptor sialo-sugar chains. , 1994, Progress in lipid research.
[137] M. Froimowitz,et al. HyperChem: a software package for computational chemistry and molecular modeling. , 1993, BioTechniques.
[138] H. Moreau,et al. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells , 1992, Journal of virology.
[139] D. Silberberg,et al. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. , 1991, Science.
[140] Barry Honig,et al. Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation , 1990 .
[141] K. Gustafson,et al. AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). , 1989, Journal of the National Cancer Institute.
[142] E. De Clercq,et al. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus , 1988, Antimicrobial Agents and Chemotherapy.
[143] S. Cusack,et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.
[144] C. J. Oss,et al. Hemagglutination and the Closest Distance of Approach of Normal, Neuraminidase‐ and Papain‐Treated Erythrocytes , 1984, Vox sanguinis.
[145] J M Blaney,et al. Electrostatic potential molecular surfaces. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[146] J. Paulson,et al. Specific gangliosides function as host cell receptors for Sendai virus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[147] D. Wolf,et al. Composition and functioin of human cervical mucus. , 1980, Biochimica et biophysica acta.
[148] W. Brodsky. Protein synthesis rhythm. , 1975 .
[149] P Sturgeon,et al. Effects of Proteases and Neuraminidase on RBC Surface Charge and Agglutination , 1975, Vox sanguinis.